Amyloid plaques are a neuropathological hallmark of Alzheimer's disease (AD), but their relationship to neurodegeneration and dementia remains controversial. In contrast, there is a good correlation in AD between cognitive decline and loss of synaptophysin-immunoreactive (SYN-IR) presynaptic terminals in specific brain regions. We used expression-matched transgenic mouse lines to compare the effects of different human amyloid protein precursors (hAPP) and their products on plaque formation and SYN-IR presynaptic terminals. Four distinct minigenes were generated encoding wild-type hAPP or hAPP carrying mutations that alter the production of amyloidogenic A␤ peptides. The platelet-derived growth factor ␤ chain promoter was used to express these constructs in neurons. hAPP mutations associated with familial AD (FAD) increased cerebral A␤ 1-42 levels, whereas an experimental mutation of the ␤-secretase cleavage site (671 M3I ) eliminated production of human A␤.
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder that causes a chronically progressive decline in cognitive functions. Because of the increasing longevity of many populations around the world, AD is a medical problem of mounting social and economic impact (Alloul et al., 1998) . The disease is associated with a characteristic combination of morphological CNS alterations, including deposition of amyloid proteins in parenchymal plaques and cerebral blood vessels, intraneuronal formation of neurofibrillary tangles, loss of presynaptic terminals and neuronal subpopulations, and reactive gliosis (Terry et al., 1999) . The severity of these alterations varies widely and specifically across different areas of the brain (Braak and Braak, 1998) , suggesting that AD preferentially affects certain types of neural elements or that these elements are particularly susceptible to the disease.
Loss of synaptophysin-immunoreactive (SYN-IR) presynaptic terminals (Terry et al., 1991; Honer et al., 1992; Masliah et al., 1994; Dickson et al., 1995; Sze et al., 1997) and the number of neurofibrillary tangles (Gomez-Isla et al., 1997) in specific brain regions correlate well with cognitive decline in AD. In contrast, the relationship between amyloid plaques and clinical manifestations or neurodegenerative changes remains controversial (Cummings et al., 1996; Terry, 1996; Bartoo et al., 1997; Davis and Chisholm, 1997; Gomez-Isla et al., 1997; Lue et al., 1999; McLean et al., 1999) . This is puzzling in light of different lines of evidence implicating the amyloid-␤ protein precursor (APP) and its metabolites in the pathogenesis of AD.
Mutations in genes encoding APP or presenilins 1 or 2 have been linked to autosomal dominant forms of familial AD (FAD), and these mutations increase the production of APP-derived A␤ peptides, either total A␤ or A␤ ending at residue 42 (A␤ 42 ) (for review, see Younkin, 1995; Price and Sisodia, 1998; Storey and Cappai, 1999) . A variety of A␤ preparations elicit neurotoxicity in cultures of neural cells or tissue sections (Yankner et al., 1989; Pike et al., 1993; Yankner, 1996; Lambert et al., 1998) , and acute injections of fibrillar A␤ into the brain induce significant neuronal loss in aged rhesus monkeys (Geula et al., 1998) .
Several transgenic mouse models have been developed to further elucidate the pathogenic role of APP/A␤ in vivo (Price and Sisodia, 1998) . Although low-level neuronal expression of wildtype or FAD-mutant human APP (hAPP) did not result in the formation of typical AD-like amyloid plaques (Quon et al., 1991; Mucke et al., 1994) , it did elicit age-related deficits in spatial learning and memory (Moran et al., 1995; D'Hooge et al., 1996) . High-level neuronal expression of FAD-mutant hAPP resulted in the brain region-dependent development of several AD-like CNS alterations, including typical neuritic plaques, reactive gliosis, and loss of SYN-IR presynaptic terminals and neuronal subpopulations (Games et al., 1995; Masliah et al., 1996; Hsia et al., 1999) . Many of these findings have been confirmed and extended in independent models expressing FADmutant hAPP in the absence (Hsiao et al., 1996; Sturchler-Pierrat et al., 1997) or presence (Duff et al., 1996; Borchelt et al., 1997) of FAD-mutant presenilins.
In some hAPP transgenic models, behavioral impairments (Hsiao et al., 1996) (but see Routtenberg, 1997) or loss of neurons (Calhoun et al., 1998) correlated with the extent of amyloid deposition. In others, behavioral impairments (Holcomb et al., 1998; Moechars et al., 1999) , synaptic transmission deficits, and loss of SYN-IR presynaptic terminals and microtubule-associated protein 2-IR neurons (Hsia et al., 1999) clearly preceded plaque formation, raising the possibility that hAPP or A␤ can induce structural and functional neuronal deficits independent of plaque formation. These discrepancies underline the need for a systematic comparison of A␤ levels, plaque formation, and neurodegeneration in transgenic lines expressing wild-type or FAD-mutant forms of hAPP at comparable levels. Here, we report the results of such an analysis.
MATERIALS AND METHODS
Animals. The platelet-derived growth factor (PDGF)-APP transgene (Games et al., 1995; Rockenstein et al., 1995) and the generation of PDGF-APP Ind line H6 (Wyss-Coray et al., 1997) and PDGF-APP Sw,Ind line J9 (Hsia et al., 1999) have been described previously. To generate PDGF-APP Wt , the sequence of PDGF-APP Ind was converted to wild type by PCR primer modification, essentially as described previously (Rockenstein et al., 1995) . To generate PDGF-APP M-I , the EcoRI to SpeI fragment of PDGF-APP Ind containing the 717 V3 F mutation was subcloned into analogous sites in pC M V695 M596I (C itron et al., 1995) to form pC M V695HaM596I. The 1.4 kb XhoI to SpeI fragment from pC M V695HaM596 was then ligated into the analogous sites of PDGF-APP Ind to create the PDGF-APP M-I transgene. The correctness of PDGF-APP Wt and PDGF-APP E xp,Ind was confirmed by sequencing across modified regions.
Microinjection of transgenes into C57BL /6 ϫ DBA /2 F2 one-cell embryos, identification of transgenic founders by slot-blot analysis of genomic DNA, and selection of lines with cerebral hAPP mRNA expression by RNase protection assay analysis were performed as described previously (Games et al., 1995; Rockenstein et al., 1995) . For each construct, several transgenic founders (PDGF-APP Wt , n ϭ 7; PDGF-APP Ind , n ϭ 12; PDGF-APP Sw,Ind , n ϭ 7; and PDGF-APP E xp,Ind , n ϭ 19) were generated, and their offspring were screened for cerebral transgene expression. Transgenic expresser lines were maintained by crossing heterozygous transgenic mice with nontransgenic C57BL /6 ϫ DBA /2 F1 breeders. All transgenic mice were heterozygous with respect to the transgene. Nontransgenic littermates served as controls.
Mice were anesthetized with chloral hydrate and flush-perf used transcardially with 0.9% saline. Brains were removed and divided sagittally. One hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde, pH 7.4, at 4°C for 48 hr for vibratome sectioning; the other was snap frozen and stored at Ϫ70°C for RNA or protein analysis.
R NA anal ysis. RNA extraction and mRNA quantitation by solution hybridization RNase protection assay were performed as described previously (Rockenstein et al., 1995) , using 10 g of total RNA per sample in combination with the following 32 P-labeled antisense riboprobes [protected nucleotides (GenBank accession number)]: hAPP [nt2468 -2657 (X06989) of hAPP f used via NotI linker with nt2532-2656 (M24914) of SV40]; actin [nt480 -559 (X03672) of mouse ␤-actin].
Quantitation of A␤. Snap-frozen hippocampi were homogenized in guanidine buffer, and human A␤ peptides were quantitated by ELISA as described previously (Johnson-Wood et al., 1997). The A␤ 1-42 ELISA detects only A␤ 1-42 , whereas the A␤ 1-x ELISA detects A␤ 1-40 , A␤ 1-42 , and A␤ 1-43 , as well as C -terminally truncated forms of A␤ containing amino acids 1-28.
Detection of A␤ deposits. Vibratome sections were incubated overnight at 4°C with biotinylated mouse monoclonal antibody 3D6 (diluted to 5 g /ml), which specifically recognizes A␤ 1-5 (Johnson-Wood et al., 1997; Wyss-Coray et al., 1997) . Binding of primary antibody was detected with the Elite kit from Vector Laboratories (Burlingame, CA) using diaminobenzidine and H 2 O 2 for development. Sections were counterstained with 1% hematoxylin and examined with a Vanox light microscope (Olympus Optical, Tokyo, Japan) using a 2.5ϫ objective. The percent area of the hippocampus covered by 3D6-immunoreactive material ("plaque load") was determined with a Quantimet 570C (Leica, Deerfield, IL). Three immunolabeled sections were analyzed per mouse, and the average of the individual measurements was used to calculate group means. Some sections were double-immunolabeled with a rabbit polyclonal antibody against A␤ (R1280; courtesy of Dr. Dennis Selkoe) and mouse monoclonal antibodies against phosphorylated neurofilaments (SM I312; Sternberger Monoclonals, Baltimore, MD) as described previously (Masliah et al., 1996) .
Densit y of SY N-IR presynaptic terminals. Vibratome sections were incubated overnight with a monoclonal antibody against synaptophysin (1 g /ml; Boehringer Mannheim, Indianapolis, I N), followed by incubation with fluorescein isothiocyanate-conjugated horse anti-mouse IgG (1:75; Vector Laboratories). Sections were then transferred to SuperFrost slides (Fisher Scientific, T ustin, CA), mounted under glass coverslips with antifading medium (Vector Laboratories), and imaged with a laser scanning confocal microscope (MRC1024; Bio-Rad, Hercules, CA) as described previously (Games et al., 1995; Masliah et al., 1996) . For each experiment, we first determined the linear range of the fluorescence intensity of immunoreactive terminals in nontransgenic control sections. This setting was then used, as described previously (Buttini et al., 1999) , to collect all images analyzed in the same experiment. For each mouse, 12 confocal images (four per section) of the molecular layer of the dentate gyrus, each covering an area of 7282 m 2 , were obtained. Digitized images were transferred to a Macintosh computer (Apple Computers, Cupertino, CA) and analyzed with N IH Image software. The area occupied by SYN-IR presynaptic terminals was quantified and expressed as a percentage of the total image area as described previously (Masliah et al., 1992b; Games et al., 1995) .
This method of quantitating SYN-IR presynaptic terminals has been used extensively to assess neurodegenerative alterations in diverse experimental models (Toggas et al., 1994; Games et al., 1995; Buttini et al., 1999) and in diseased human brains (Masliah et al., 1991b (Masliah et al., , 1992a Knowles et al., 1998) . It has also been validated previously by comparisons with quantitative immunoblots Mucke et al., 1994) , quantitations of synaptic proteins by ELISA (Brown et al., 1998; Buttini et al., 1999) , and the optical "disector" approach (Masliah et al., 1991a; Everall et al., 1999; Hsia et al., 1999) . To ensure objective assessments and reliability of results, brain sections from mice to be compared in any given experiment were blind coded and processed in parallel. Codes were broken after the analysis was complete.
Statistical anal yses. Statistical analyses were performed with the StatView 5.0 program (SAS Institute Inc., C ary, NC). Differences among means were assessed by one-way ANOVA followed by, Dunnett's or T ukey -Kramer post hoc test. Correlation studies were performed by simple regression analysis. The null hypothesis was rejected at the 0.05 level.
RESULTS

Generation of transgenic mice expressing wild-type and FAD-mutant hAPP at comparable levels
The PDGF ␤ chain promoter was used to direct neuronal expression of alternatively spliced minigenes encoding hAPP695, hAPP751, and hAPP770, as described previously (Games et al., 1995; Rockenstein et al., 1995) . Four types of hAPP were expressed individually in different lines of transgenic mice ( Fig. 1) : wild-type hAPP (APP Wt ), hAPP carrying the FAD-linked (Murrell et al., 1991) 717 V3 F mutation (APP Ind ), hAPP carrying the 717 V3 F mutation plus the FAD-linked (Mullan et al., 1992) 670/671 K M3 N L double mutation (APP Sw,Ind ), and hAPP carrying the 717 V3 F mutation plus an experimental 671 M3 I mutation (APP E xp,Ind ) that inhibits A␤ production in cell culture (Citron et al., 1995) . Several independent lines of transgenic mice were established for each construct: 7 for APP Wt , 11 for APP Ind , 7 for APP Sw,Ind , and 15 for APP E xp,Ind . The generation of APP Ind line H6 (Wyss-Coray et al., 1997) and APP Sw,Ind line J9 (Hsia et al., 1999) has been described previously.
The overall level of cerebral transgene expression in each line was determined by RNase protection assay (Fig. 2) . Based on this analysis, three groups of transgenic lines, each consisting of two or more lines expressing different hAPP constructs at comparable levels, were selected for further analysis (Fig. 1 B) . Cerebral hAPP mRNA levels in the highest expresser lines, APP Wt I63 and APP Ind H6, are similar to those in the APP Ind line 109 described previously (Games et al., 1995; Rockenstein et al., 1995) . Although we were able to generate lines representing a broad range of expression levels for APP Wt , APP Ind , and APP Sw,Ind , all APP E xp,Ind lines in which hAPP mRNA could be detected in the brain (n ϭ 15) had low levels of transgene expression ( Fig. 1 B and data not shown). The reasons for this remain to be determined.
In all PDGF-APP mice, cerebral expression of hAPP immunoreactivity was primarily neuronal and widespread across different brain regions, with maximal levels in the neocortex and hippocampus (data not shown), consistent with previous observations (Games et al., 1995; Johnson-Wood et al., 1997) .
Effects of hAPP mutations on human A␤ levels
Neocortical and hippocampal levels of A␤ 1-x , approximating total A␤ Gouras et al., 1998) , and A␤ 1-42 were determined by ELISA. Because intraparenchymal A␤ deposits significantly increase the overall A␤ burden, as measured by ELISA , the effects of hAPP mutations on cerebral A␤ production were evaluated at 2-4 months of age, when brains of transgenic mice from all lines were devoid of 3D6-immunoreactive A␤ deposits (see below).
For any given construct, levels of A␤ 1-x and A␤ 1-42 (Fig. 3 ) were dependent on overall transgene expression levels (Figs. 1, 2) , with the highest A␤ levels seen in the highest hAPP expresser lines. In both the hippocampus (Fig. 3) and neocortex (data not shown), the 717 V3 F mutation increased the relative proportion of A␤ 1-42 without increasing A␤ 1-x levels, whereas the 670/ 671 K M3 N L double mutation significantly increased A␤ 1-x levels, FAD-linked mutations are commonly referred to by place of discovery or residence of affected kindred. The 670/ 671 KM3 NL double mutation affects a large pedigree in Sweden (Mullan et al., 1992) , and the 717 V3 F mutation was identified in Indiana (Murrell et al., 1991) (numbers refer to amino acids in APP770). Mutations at position 717 are often collectively referred to as "London mutations" based on the first report of the FAD-linked 717 V3 I mutation (Goate et al., 1991) ; however, the latter mutation was not studied here. The sequence of A␤ is indicated in bold in single-letter amino acid code. KPI, Kunitz-type protease inhibitor domain. Elements are not drawn to scale. B, Relative levels of cerebral transgene expression (values in parentheses) were determined in different lines of PDGF-hAPP mice as illustrated in Figure 2 . The expression level in line I63 was arbitrarily defined as 1.0. consistent with previous observations (Citron et al., 1992; Cai et al., 1993; Younkin, 1995) . Consequently, for a given level of transgene expression, A␤ levels were lower in APP Wt mice than in APP Sw,Ind mice (Figs. 1-3) . No human A␤ could be detected in brains of mice expressing hAPP carrying the experimental 671 M3 I mutation, confirming in vivo the effects this mutation has in vitro (Citron et al., 1995) .
Effects of hAPP mutations on formation of amyloid plaques
To assess plaque formation, sections from transgenic and nontransgenic mice were immunolabeled with a monoclonal antibody against A␤ (3D6). At 5-7 months of age, amyloid deposition was detected only in APP Sw,Ind mice (Fig. 4) . Diffuse amyloid immunoreactivity at this age was observed in a laminar pattern in the molecular layer of the dentate gyrus, and a few dense amyloid deposits 4 -10 m in diameter were detected in the deeper layers of the neocortex (data not shown). Both the diffuse plaques and the microplaques lacked a neuritic component. No plaques were detected at 5-7 months in transgenic mice from APP Wt lines I5 and I63 or APP Ind lines H6 and H40 (7-17 mice per line). At 8 -10 months of age, APP Sw,Ind lines also had the highest proportion of mice with plaques (Fig. 4) , compared with hAPP expressionmatched APP Ind mice, and the highest hippocampal plaque loads (Fig. 5 and data not shown) . In both APP Ind and APP Sw,Ind mice, the onset and extent of plaque formation were influenced by levels of human A␤, with mice expressing higher levels of A␤ showing earlier and more extensive amyloid deposition (Figs. 3-5), even among lines that were well matched for overall transgene expression (Figs. 1, 2) . At 21-27 months of age, the proportion of APP Ind mice with plaques increased to 93% in the high expresser H6 line and to 83% in the low expresser H40 line (Fig.  4) . Plaques in adult mice were typically larger and denser than those in young mice and showed a prominent neuritic component when double-labeled with antibodies against A␤ and neurofilaments (Fig. 5E) . No plaques were detected in nontransgenic mice at 2-27 months of age (n ϭ 84).
Decreased levels of SYN-IR presynaptic terminals are unrelated to plaque load
We showed previously that transgenic mice expressing FADmutant hAPP have a decreased density of SYN-IR presynaptic terminals in specific subfields of the hippocampus and that this decrease precedes plaque formation (Games et al., 1995; Hsia et al., 1999) . Because diverse factors associated with aging could link parallel processes in time, simulating cause-effect relationships that may not exist, it is critical to compare the effects of plaque load on neurodegeneration within relatively narrow age ranges. To assess whether plaque formation in FAD-mutant hAPP lines exacerbates the decrease in SYN-IR presynaptic terminals in old mice, we compared hippocampal density of SYN-IR presynaptic terminals and plaque load in APP Ind and APP Sw,Ind mice at 21-27 months of age, when most of these mice have plaques (see above). No correlation was identified between SYN-IR presynaptic terminals and plaque load (Fig. 6) . At 8 -10 months of age, when some mice have plaques and others do not (Fig. 4) , the density of SYN-IR presynaptic terminals also did not correlate with plaque load in APP Ind mice from line H6 (n ϭ 24, r ϭ 0.015, p ϭ 0.94) or APP Sw,Ind mice from lines J9 and J20 (n ϭ 16, r ϭ 0.28, p ϭ 0.29). 
APP Wt mice with high A␤ levels do not develop plaques but have decreased levels of SYN-IR presynaptic terminals
Although A␤ 1-42 levels in the APP Wt line I63 were similar to those in the plaque-bearing APP Ind line H6 (Fig. 7A) , no plaques were detected in mice from APP Wt line I63 between 2 and 28 months of age (Figs. 5, 7B ). Mice from APP Wt line I5 also had no plaques at 8 -10 (n ϭ 9 mice) or 24 (n ϭ 2) months of age (data not shown). Despite the lack of plaque formation, mice from APP Wt line I63 showed decreases in SYN-IR presynaptic terminals similar to those in mice from APP Ind line H6 (Fig. 7C) . Simple regression analysis revealed a significant decline in SYN-IR presynaptic terminals with age (age range of 2-28 months) in mice from APP Ind line H6 (n ϭ 56, r ϭ 0.30, p ϭ 0.0243) and APP Wt line I63 (n ϭ 23, r ϭ 0.53, p ϭ 0.0095) but not in nontransgenic controls (n ϭ 87, r ϭ 0.07, p ϭ 0.53). Because APP Ind line H6 and APP Wt line I63 are well matched not only for A␤ (Figs. 3, 7A ) but also for overall transgene expression (Figs. 1, 2) , their comparable decrease in SYN-IR presynaptic terminals could be attributable to neuronal overexpression of either A␤ 1-42 or hAPP. To elucidate the relative importance of hAPP and A␤ in determining the density of SYN-IR presynaptic terminals in these models, we took advantage of the fact that hAPP expression-matched APP Wt , APP Ind , and APP Sw,Ind mice have different levels of A␤ 1-42 production. The density of SYN-IR presynaptic terminals and levels of hAPP and its products were assessed in 2-to 4-month-old mice, because at this age, decreases in SYN-IR presynaptic terminals are already detectable in transgenic mice (Fig. 7C) , and steady-state levels of A␤ can be assessed most reliably because none of the mice have plaques (Fig. 4) . First, we examined the relationship between the density of SYN-IR presynaptic terminals and hAPP levels. We found no correlation between these variables across different lines of transgenic mice (Fig. 8) . Next, we examined whether there was evidence for dose-dependent synaptotoxicity of A␤. A significant inverse correlation was identified between the density of SYN-IR presynaptic terminals and the levels of A␤ 1-x or A␤ (Fig. 9) .
DISCUSSION
High-level neuronal production of A␤ 1-42 in mice expressing wild-type hAPP did not result in the formation of amyloid plaques but was associated with decreased levels of SYN-IR presynaptic terminals in the molecular layer of the dentate gyrus. Across different wild-type and FAD-mutant hAPP transgenic lines, decreases in SYN-IR presynaptic terminals correlated with A␤ levels but not with hAPP levels or plaque load. These results support a plaque-independent role for A␤ in AD-related synaptic toxicity.
Plaque formation depends on both absolute levels of A␤ 1-42 and A␤ 1-42 /A␤ 1-40 ratio
In transgenic lines carrying FAD mutations, the onset and progression of plaque formation were closely related to levels of A␤ 1-42 expression measured before the development of plaque pathology. In hAPP expression-matched lines containing the 717 V3 F mutation, plaque formation was accelerated and intensified by the 670/671 K M3 N L double mutation, which increases A␤ production (Citron et al., 1992; Cai et al., 1993; Younkin, 1995) . These findings suggest that critical levels of A␤ 1-42 in vulnerable brain regions are necessary for the development of plaques. However, the absence of plaques in line I63 demonstrates that high levels of A␤ 1-42 are not sufficient for plaque formation. Line I63 is, to our knowledge, the first APP Wt transgenic line that produces A␤ 1-42 levels comparable with those in FAD-mutant hAPP mice that develop plaques. The close match in hAPP and A␤ 1-42 levels in APP Wt line I63 and APP Ind line H6 was fortuitous but exceptional, because in other APP Ind lines the 717 V3 F mutation increased A␤ 1-42 levels over those identified in APP Wt lines. We cannot exclude the possibility that the difference in plaque formation between wild-type and FAD-mutant hAPP lines involves A␤-independent factors. However, for the following reasons, we favor the hypothesis that differences in A␤ 1-42 /A␤ 1-x ratios play a key role. For unknown reasons, A␤ 1-x levels were higher in APP Wt line I63 than in APP Ind line H6, resulting in a lower A␤ 1-42 /A␤ 1-x ratio in line I63 (Figs. 3, 7) . Compared with APP Wt line I63, APP Ind line H40 had lower A␤ 1-x levels but comparable A␤ 1-42 levels (Fig. 3) . The higher A␤ 1-42 /A␤ 1-x ratio in line H40 was associated with plaque formation, whereas the lower A␤ 1-42 /A␤ 1-x ratio in line I63 was not. A␤ 1-40 accounts for most of the A␤ 1-x that does not end at A␤ residue 42 (Gouras et al., 1998) . It is conceivable that A␤ 1-40 interferes with A␤ 1-42 aggregation in vivo, as it does in vitro (Snyder et al., 1994) , and that the lack of plaque formation in line I63 reflects an antiamyloidogenic effect of A␤ . If confirmed in future studies, this effect could be exploited therapeutically.
Synaptotoxicity depends on A␤ levels but not hAPP levels, plaque load, or presence of FAD mutations
Decreases in synaptophysin immunoreactivity in specific brain regions correlate well with the severity of cognitive deficits in AD Figure 7 . Comparison of hippocampal A␤ levels, plaque formation, and density of SYN-IR presynaptic terminals in the high expresser lines APP Wt I63 and APP Ind H6. Note that the cerebral hAPP mRNA levels in these lines are very well matched (Figs. 1, 2) . A, Levels of human A␤ were determined at 2-4 months of age in 8 -9 mice per line by ELISA. Circles represent values in individual mice; horizontal lines indicate group means. B, Proportion of mice in which 3D6-immunoreactive plaques were identified (black) at the ages indicated (n ϭ 4 -18 mice per line and age range). C, The density of SYN-IR presynaptic terminals was determined in 4 -41 mice per genotype and age range. Data represent group means Ϯ SD. *p Ͻ 0.05, **p Ͻ 0.01 versus nontransgenic controls (Tukey-Kramer post hoc test). Figure 8 . Density of SYN-IR presynaptic terminals does not correlate with hAPP levels across hAPP mice from different lines. Levels of fulllength plus ␣-secreted hAPP and density of SYN-IR presynaptic terminals in the hippocampus were determined in 36 transgenic mice from APP Wt lines I5, I7, and I63, APP Ind lines H6 and H40, and APP Sw, Ind line J9 at 2-4 months of age. No correlation was identified between the two variables. No plaques were detected in the opposite hemibrains of these mice by immunostaining with the 3D6 antibody (data not shown). (Terry et al., 1991; Honer et al., 1992; Masliah et al., 1994; Dickson et al., 1995; Sze et al., 1997) , highlighting the clinical relevance of this marker. Compared with the decreases in SYN-IR presynaptic terminals in late stages of AD (40%) , the decreases we found in hAPP transgenic mice (10 -30%) may seem relatively subtle. However, the decreases in SYN-IR presynaptic terminals in hAPP mice were not only statistically significant but were also associated with major synaptic transmission deficits (Hsia et al., 1999) , supporting their pathophysiological relevance.
In all transgenic models in which A␤ is expressed from the full-length precursor molecule, overexpression of A␤ is inseparably linked to overexpression of hAPP itself. Because hAPP could affect neuronal function through a number of mechanisms (Milward et al., 1992; Mattson et al., 1993; Greenberg et al., 1994; Multhaup et al., 1996; Okamoto et al., 1996; Masliah et al., 1998) , it is important to determine whether hAPP per se is responsible for the neuropathological alterations in these models. In transgenic mice expressing hAPP from the relatively weak neuronspecific enolase promoter, levels of SYN-IR presynaptic terminals were increased in mice with lower levels of hAPP expression but not in mice with higher levels of hAPP expression . Those results led us to postulate a bell-shaped doseresponse curve for synaptotrophic effects of hAPP at nearphysiological levels of hAPP expression . The relatively high density of SYN-IR presynaptic terminals in the low expresser APP Wt line I7 (Fig. 9 ) may be consistent with this hypothesis. At higher levels of hAPP expression, the density of SYN-IR presynaptic terminals did not correlate with hAPP levels, suggesting that hAPP overexpression per se is not responsible for the decreased density of these structures in hAPP mice.
Although the high expresser APP Wt line I63 did not develop plaques, it showed significant decreases in SYN-IR presynaptic terminals that worsened with age. Thus, FAD mutations are not required for the decrease in SYN-IR presynaptic terminals in hAPP mice, consistent with the loss of these structures in humans with sporadic AD, who also lack FAD mutations. The decreased levels of SYN-IR presynaptic terminals in line I63 also demonstrate that plaques are not required for this deficit to occur. Moreover, across different lines of aged plaque-bearing mice, plaque load did not correlate with the density of SYN-IR presynaptic terminals. If not extracellular deposits of fibrillar A␤, what is causing the synaptic deficits? Possibilities include neurotoxic effects induced by the intraneuronal accumulation of A␤ or by diffusible forms of extracellular A␤ (Masliah et al., 1996; Turner et al., 1996; Lambert et al., 1998; Lee et al., 1998; Hartley et al., 1999; Hsia et al., 1999; Wilson et al., 1999) . Consistent with either of these possibilities and with recent findings in AD (Lue et al., 1999; McLean et al., 1999) , decreases in SYN-IR presynaptic terminals in transgenic lines expressing wild-type or FADmutant hAPP correlated inversely and plaque-independently with levels of A␤ 1-x and A␤ 1-42 .
In conclusion, our findings suggest that plaque formation is influenced not only by absolute but also by relative levels of A␤ 1-42 and A␤ 1-40 , with relatively high concentrations of A␤ 1-40 being potentially antiamyloidogenic. Decreases in SYN-IR presynaptic terminals were critically dependent on A␤ levels but not on hAPP levels, plaque formation, or presence of FAD mutations, suggesting that plaque-independent A␤ toxicity could play a key role in the pathogenesis of AD-related neurodegeneration. Figure 9 . Inverse correlation between density of SYN-IR presynaptic terminals and levels of A␤. At 2-4 months of age, hippocampal levels of A␤ 1-x and A␤ 1-42 in one hemibrain were correlated with the hippocampal density of SYN-IR presynaptic terminals in the opposite hemibrain in mice from lines expressing APP Wt , APP Ind , or APP Sw, Ind at different levels (4 -9 mice per line). None of these mice had plaques by immunostaining with the 3D6 antibody (data not shown). Arrows indicate the normal density of SYN-IR presynaptic terminals in age-matched nontransgenic controls (mean of 29 mice).
